Program
RO7821657
A development code.
Its studies are led by Hoffmann-La Roche.
Furthest: phase 1, since Oct 14, 20261 company-led study, 1 open or runningNext primary completion: May 31, 2030 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 11 open or running | phase 1since Oct 14, 2026 | Oct 14, 2026 | May 31, 2030phase 1 · NCT07883577 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 14, 2026First study: phase 1 study in Locally Advanced or Metastatic Solid TumorsFirst studyNCT07883577 · 405 planned · Denmark, United Kingdom
Ahead
- May 31, 2030Primary completion: phase 1 study in Locally Advanced or Metastatic Solid TumorsNCT07883577
TargetBeta
CEACAM5 →read by rule
“A First In-Human, Multicenter, Phase I Clinical Study of RO7821657, a Protease Activated TCB Antibody That Targets CEACAM5, in Participants With Locally Advanced and/or Metastatic Solid Tumors”study text, by rule · the study
Other programs on CEACAM5
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| precemtabart tocentecanrule | Merck KGaA, Darmstadt, Germany | phase 3 | 4 |
| Anti-CEA/Anti-4-1BB Bispecific Antibody LM-24C5 | Sino Biopharmaceutical | phase 2 | 2 |
| Anti-CEACAM5 Antibody-drug Conjugate BMS-986490rule | Bristol-Myers Squibb | phase 2 | 1 |
| Anti-CEACAM5 Antibody-drug Conjugate IBI3020rule | Innovent Biologics | phase 1 | 1 |
| tusamitamab sonditecan | Pfizer | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07883577Locally Advanced or Metastatic Solid Tumors · Denmark, United Kingdom | 1 | Recruiting | May 31, 2030 | 405 |
How it is read
Names in the registry
- “RO7821657”, 1 entry
Codes read as this program: RO7821657.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.